menu
    • menu
    [{"orgOrder":0,"company":"Kalbe Genexine Biologics","sponsor":"Novotech","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"INDONESIA","productType":"Protein","year":"2019","type":"Inapplicable","leadProduct":"Efepoetin Alfa","moa":"Erythropoietin receptor","graph1":"Nephrology","graph2":"Phase III","graph3":"Kalbe Genexine Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kalbe Genexine Biologics \/ Novotech","highestDevelopmentStatusID":"10","companyTruncated":"Kalbe Genexine Biologics \/ Novotech"},{"orgOrder":0,"company":"Kalbe Genexine Biologics","sponsor":"Genexine","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SOUTH KOREA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Efepoetin Alfa","moa":"Erythropoietin receptor","graph1":"Nephrology","graph2":"Phase III","graph3":"Kalbe Genexine Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kalbe Genexine Biologics \/ Kalbe Genexine Biologics","highestDevelopmentStatusID":"10","companyTruncated":"Kalbe Genexine Biologics \/ Kalbe Genexine Biologics"},{"orgOrder":0,"company":"Kalbe Genexine Biologics","sponsor":"Genexine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Protein","year":"2021","type":"Licensing Agreement","leadProduct":"Efineptakin Alpha","moa":"IL-7 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Kalbe Genexine Biologics","amount2":1.1000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":1.1000000000000001,"dosageForm":"Injection","sponsorNew":"Kalbe Genexine Biologics \/ Kalbe Genexine Biologics","highestDevelopmentStatusID":"6","companyTruncated":"Kalbe Genexine Biologics \/ Kalbe Genexine Biologics"},{"orgOrder":0,"company":"Kalbe Genexine Biologics","sponsor":"Genexine","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDONESIA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"GX-I7","moa":"IL-7 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Kalbe Genexine Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kalbe Genexine Biologics \/ Genexine","highestDevelopmentStatusID":"8","companyTruncated":"Kalbe Genexine Biologics \/ Genexine"},{"orgOrder":0,"company":"Kalbe Genexine Biologics","sponsor":"I-Mab Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Partnership","leadProduct":"Uliledlimab","moa":"monoclonal antibodies: immunomodulating","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kalbe Genexine Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kalbe Genexine Biologics \/ Kalbe Genexine Biologics","highestDevelopmentStatusID":"7","companyTruncated":"Kalbe Genexine Biologics \/ Kalbe Genexine Biologics"},{"orgOrder":0,"company":"Kalbe Genexine Biologics","sponsor":"Shanghai Henlius Biotech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Licensing Agreement","leadProduct":"Serplulimab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Kalbe Genexine Biologics","amount2":0.67000000000000004,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.67000000000000004,"dosageForm":"Injection","sponsorNew":"Kalbe Genexine Biologics \/ Kalbe Genexine Biologics","highestDevelopmentStatusID":"15","companyTruncated":"Kalbe Genexine Biologics \/ Kalbe Genexine Biologics"},{"orgOrder":0,"company":"Kalbe Genexine Biologics","sponsor":"Genexine","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SOUTH KOREA","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Efepoetin Alpha","moa":"Undisclosed","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Kalbe Genexine Biologics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kalbe Genexine Biologics \/ Kalbe Genexine Biologics","highestDevelopmentStatusID":"15","companyTruncated":"Kalbe Genexine Biologics \/ Kalbe Genexine Biologics"}]

    Find Clinical Drug Pipeline Developments & Deals by Kalbe Genexine Biologics

    Menu

    Kalbe Genexine Biologics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Kalbe Genexine Biologics

                            Indonesia arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Kalbe Genexine Biologics

                            Indonesia arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Efepoetin Alfa

                            Therapeutic Area : Nephrology

                            Study Phase : Phase III

                            Recipient : Genexine

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Phase 3 Study of Efepoetin Alfa for Treatment of Anemia in Patients With Chronic Kidney Disease on Dialysis

                            Details : Efepoetin Alfa is a Protein drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Anemia-associated with Renal Insufficiency, Chronic.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            June 20, 2024

                            Lead Product(s) : Efepoetin Alfa

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase III

                            Recipient : Genexine

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Kalbe Genexine Biologics

                            Indonesia arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Kalbe Genexine Biologics

                            Indonesia arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Efepoetin Alpha

                            Therapeutic Area : Nephrology

                            Study Phase : Approved FDF

                            Recipient : Genexine

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Genexine and KGbio Received the First Market Approval for Novel Long-acting Erythropoietin, Efepoetin Alfa, fr...

                            Details : Efesa (efepoetin alfa) is a bio-better drug for CKD-induced anemia, developed based on hyFc®, Genexine's proprietary long-acting platform technology, which is investigated for the treatment of chronic kidney disease induced anemia in non-dialysis patien...

                            Product Name : Efesa

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            October 23, 2023

                            Lead Product(s) : Efepoetin Alpha

                            Therapeutic Area : Nephrology

                            Highest Development Status : Approved FDF

                            Recipient : Genexine

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Kalbe Genexine Biologics

                            Indonesia arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Kalbe Genexine Biologics

                            Indonesia arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Serplulimab

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Recipient : Shanghai Henlius Biotech

                            Deal Size : $665.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Henlius Expands Collaboration with KGbio to Develop, Commercialize and Supply Henlius' novel anti-PD-1 mAb HAN...

                            Details : Under the terms of the agreement, Henlius will be responsible for development and commercialisation of Hansizhuang (serplulimab injection) as a treatment for two indications including ES-SCLC, Henlius' novel anti-PD-1 mAb, in 12 MENA countries.

                            Product Name : Hansizhuang

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : $7.0 million

                            September 12, 2023

                            Lead Product(s) : Serplulimab

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Recipient : Shanghai Henlius Biotech

                            Deal Size : $665.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Kalbe Genexine Biologics

                            Indonesia arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Kalbe Genexine Biologics

                            Indonesia arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GX-I7

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Genexine

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Evaluate the Safety and Efficacy of GX-I7 in Elderly Patients With Asymptomatic or Mild Symptoms of...

                            Details : GX-I7 is a Protein drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of COVID-19.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            March 23, 2021

                            Lead Product(s) : GX-I7

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Genexine

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Kalbe Genexine Biologics

                            Indonesia arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Kalbe Genexine Biologics

                            Indonesia arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Efineptakin Alpha

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : Genexine

                            Deal Size : $1,100.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            KGBio and Genexine Signed Immuno-Oncology Drug License Agreement GX-17

                            Details : Through this licensing agreement, KGBio and Genexine aim to develop a and commercialize an immuno-oncology drug GX-I7 (Efineptakin Alpha), namely long-acting interleukin-7 which uses the Genexine hyFc technology platform.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : $27.0 million

                            February 18, 2021

                            Lead Product(s) : Efineptakin Alpha

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : Genexine

                            Deal Size : $1,100.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Kalbe Genexine Biologics

                            Indonesia arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Kalbe Genexine Biologics

                            Indonesia arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Uliledlimab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : I-Mab Biopharma

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            I-Mab Enters into Strategic Regional Partnership with Kalbe Genexine Biologics

                            Details : KG Bio will receive a right of first negotiation for an exclusive license for the commercialization of two I-Mab discovered product candidates.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Undisclosed

                            March 30, 2020

                            Lead Product(s) : Uliledlimab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : I-Mab Biopharma

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Kalbe Genexine Biologics

                            Indonesia arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Kalbe Genexine Biologics

                            Indonesia arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Efepoetin Alfa

                            Therapeutic Area : Nephrology

                            Study Phase : Phase III

                            Sponsor : Novotech

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of Efepoetin Alfa in Treating Anaemia Associated With Chronic Kidney Diseases Patient

                            Details : Efepoetin Alfa is a Protein drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Anemia-associated with Renal Insufficiency, Chronic.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            November 07, 2019

                            Lead Product(s) : Efepoetin Alfa

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase III

                            Sponsor : Novotech

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth